140 related articles for article (PubMed ID: 38105274)
1. Magnetic resonance image-based brain age as a discriminator of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HW; Kim HJ; Lee H; Yang H; Rieu Z; Lee JH
Sci Rep; 2023 Dec; 13(1):22467. PubMed ID: 38105274
[TBL] [Abstract][Full Text] [Related]
2. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
[TBL] [Abstract][Full Text] [Related]
4. Early Impairment in the Ventral Visual Pathway Can Predict Conversion to Dementia in Patients With Amyloid-negative Amnestic Mild Cognitive Impairment.
Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kang DW; Kwon M; Kim JS; Lee JH
Alzheimer Dis Assoc Disord; 2021 Oct-Dec 01; 35(4):298-305. PubMed ID: 34132669
[TBL] [Abstract][Full Text] [Related]
5. The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kwon M; Kim JS; Kim BJ; Lee JH
Eur J Neurol; 2021 May; 28(5):1520-1527. PubMed ID: 33559375
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
7. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
8. Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Arlt S; Buchert R; Spies L; Eichenlaub M; Lehmbeck JT; Jahn H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):335-44. PubMed ID: 22940716
[TBL] [Abstract][Full Text] [Related]
9. Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia.
Kikukawa T; Abe T; Ataka S; Saito H; Hasegawa I; Mino T; Takeuchi J; Kawabe J; Wada Y; Watanabe Y; Itoh Y
Neurol Sci; 2018 Sep; 39(9):1597-1602. PubMed ID: 29936556
[TBL] [Abstract][Full Text] [Related]
10. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
Inui Y; Ito K; Kato T;
J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
[TBL] [Abstract][Full Text] [Related]
11. Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment.
Moon B; Kim S; Park YH; Lim JS; Youn YC; Kim S; Jang JW;
J Alzheimers Dis; 2017; 58(4):1255-1264. PubMed ID: 28550264
[TBL] [Abstract][Full Text] [Related]
12. Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.
Alegret M; Cuberas-Borrós G; Espinosa A; Valero S; Hernández I; Ruíz A; Becker JT; Rosende-Roca M; Mauleón A; Sotolongo O; Castell-Conesa J; Roca I; Tárraga L; Boada M
J Alzheimers Dis; 2014; 41(3):739-48. PubMed ID: 24685632
[TBL] [Abstract][Full Text] [Related]
13. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
[TBL] [Abstract][Full Text] [Related]
14. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
15. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
16. Combining neuropsychological and structural neuroimaging indicators of conversion to Alzheimer's disease in amnestic mild cognitive impairment.
Venneri A; Gorgoglione G; Toraci C; Nocetti L; Panzetti P; Nichelli P
Curr Alzheimer Res; 2011 Nov; 8(7):789-97. PubMed ID: 22175662
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.
Grimmer T; Wutz C; Drzezga A; Förster S; Förstl H; Ortner M; Perneczky R; Kurz A
Curr Alzheimer Res; 2013 Jan; 10(1):82-5. PubMed ID: 23036071
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
